Abstract
Ribotoxins constitute a family of toxic extracellular fungal RNases that exert a highly specific activity on a conserved region of the larger molecule of rRNA, known as the sarcin – ricin loop. This cleavage of a single phosphodiester bond inactivates the ribosome and leads to protein synthesis inhibition and cell death. In addition to this ribonucleolytic activity, ribotoxins can cross lipid membranes in the absence of any known protein receptor. This ability is due to their capacity to interact with acid phospholipid-containing membranes. Both activities together explain their cytotoxic character, being rather specific when assayed against some transformed cell lines. The determination of high-resolution structures of some ribotoxins, the characterization of a large number of mutants, and the use of lipid model vesicles and transformed cell lines have been the tools used for the study of their mechanism of action at the molecular level. The present knowledge suggests that wild-type ribotoxins or some modified variants might be used in human therapies. Production of hypoallergenic mutants and immunotoxins designed against specific tumors stand out as feasible alternatives to treat some human pathology in the mid-term future.
Keywords: Asp f 1, fungal allergy, immunotoxin, restrictocin, Rnase, α-sarcin
Current Pharmaceutical Biotechnology
Title: The Therapeutic Potential of Fungal Ribotoxins
Volume: 9 Issue: 3
Author(s): Nelson Carreras-Sangra, Elisa Alvarez-Garcia, Elias Herrero-Galan, Jaime Tome, Javier Lacadena, Jorge Alegre-Cebollada, Mercedes Onaderra, Jose G. Gavilanes and Alvaro Martinez-del-Pozo
Affiliation:
Keywords: Asp f 1, fungal allergy, immunotoxin, restrictocin, Rnase, α-sarcin
Abstract: Ribotoxins constitute a family of toxic extracellular fungal RNases that exert a highly specific activity on a conserved region of the larger molecule of rRNA, known as the sarcin – ricin loop. This cleavage of a single phosphodiester bond inactivates the ribosome and leads to protein synthesis inhibition and cell death. In addition to this ribonucleolytic activity, ribotoxins can cross lipid membranes in the absence of any known protein receptor. This ability is due to their capacity to interact with acid phospholipid-containing membranes. Both activities together explain their cytotoxic character, being rather specific when assayed against some transformed cell lines. The determination of high-resolution structures of some ribotoxins, the characterization of a large number of mutants, and the use of lipid model vesicles and transformed cell lines have been the tools used for the study of their mechanism of action at the molecular level. The present knowledge suggests that wild-type ribotoxins or some modified variants might be used in human therapies. Production of hypoallergenic mutants and immunotoxins designed against specific tumors stand out as feasible alternatives to treat some human pathology in the mid-term future.
Export Options
About this article
Cite this article as:
Carreras-Sangra Nelson, Alvarez-Garcia Elisa, Herrero-Galan Elias, Tome Jaime, Lacadena Javier, Alegre-Cebollada Jorge, Onaderra Mercedes, Gavilanes G. Jose and Martinez-del-Pozo Alvaro, The Therapeutic Potential of Fungal Ribotoxins, Current Pharmaceutical Biotechnology 2008; 9 (3) . https://dx.doi.org/10.2174/138920108784567335
DOI https://dx.doi.org/10.2174/138920108784567335 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Targets of Curcumin
Current Drug Targets Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?
Current Pharmaceutical Design Kidney Diseases and Chemokines
Current Drug Targets Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Iron Chelators in Cancer Chemotherapy
Current Topics in Medicinal Chemistry Natural Killer Cell Receptors in Human Immunodeficiency Virus Infection: Pathways to Protection or Doors to Disappointment?
Current HIV Research Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Recent Developments in Receptor-Selective Retinoids
Current Pharmaceutical Design Imaging Methods in Gene Therapy of Cancer
Current Gene Therapy β -Glucans and their Applications in Cancer Therapy: Focus on human studies
Anti-Cancer Agents in Medicinal Chemistry Antitumour Metallocenes: Structure-Activity Studies and Interactions with Biomolecules.
Current Medicinal Chemistry The Design of Amphiphilic Polymeric Micelles of Curcumin for Cancer Management
Current Medicinal Chemistry Nuclear Magnetic Resonance Spectroscopy of Lipids in Cancer
Current Organic Chemistry The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Nanocarriers to Solid Tumors: Considerations on Tumor Penetration and Exposure of Tumor Cells to Therapeutic Agents
Current Pharmaceutical Biotechnology Synthesis and Antitumour Activity of the Primin (2-methoxy-6-n-pentyl-1,4-benzoquinone) and Analogues
Medicinal Chemistry The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging Radioprotective and Anticancer Efficacies of Ganoderma Lucidum in a Mouse Tumor Model
Current Traditional Medicine